Glaukos Corporation Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit hit 52-week highs March 5.) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturu

Equities analysts predict that Glaukos Corp (NYSE:GKOS) will report earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estima

Glaukos (NYSE:GKOS) and Soliton (NASDAQ:SOLY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, ea

10X Genomics (NASDAQ:TXG) initiated with Buy rating and $95 (23% upside) price target at Guggenheim.Abbott (NYSE:ABT) initiated with Buy rating at Citigroup. Shares down 1% premarket.Alcon (NYSE:ALC

Brokerages expect that Glaukos Corp (NYSE:GKOS) will announce $61.06 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Glaukos’ earnings, w

Fmr LLC increased its stake in shares of Glaukos Corp (NYSE:GKOS) by 11.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.

Dublin, March 03, 2020 -- The "Global Surgical Ophthalmology Market - Analysis By Surgery Type, Product, End User, By Region, By Country (2020 Edition): Market Insight,.

Shares of Glaukos Corp (NYSE:GKOS) dropped 3% on Monday after Stifel Nicolaus lowered their price target on the stock from $59.00 to $55.00. Stifel Nicolaus currently has a hold rating on the stock. G

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

Glaukos (GKOS) fourth-quarter results benefit from revenue growth. However, rise in operating expenses remains a concern.

Aviva PLC acquired a new stake in shares of Glaukos Corp (NYSE:GKOS) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fi

In a report issued on February 27, Ryan Zimmerman from BTIG maintained a Hold rating on Glaukos (GKOS – Research

Glaukos (NYSE:GKOS) had its price target dropped by research analysts at Stephens from $80.00 to $69.00 in a research note issued on Friday, The Fly reports. The firm currently has an “overweight”

Glaukos (NYSE:GKOS) was downgraded by equities researchers at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research report issued on Friday, MarketBeat reports.

Shares of Glaukos Corp (NYSE:GKOS) reached a new 52-week low on Friday after Stifel Nicolaus lowered their price target on the stock from $59.00 to $55.00. Stifel Nicolaus currently has a hold rating